Short‐term outcome after high‐intensity focused ultrasound in the treatment of patients with high‐risk prostate cancer

OBJECTIVE To assess the short‐term outcome in patients with high‐risk prostate cancer treated by transrectal high‐intensity focused ultrasound (HIFU). PATIENTS AND METHODS From April 2003 to November 2004, 30 patients with high‐risk prostate cancer were enrolled in this prospective study; all had tr...

Full description

Saved in:
Bibliographic Details
Published in:BJU international 2006-12, Vol.98 (6), p.1193-1198
Main Authors: Ficarra, Vincenzo, Antoniolli, Stefano Zecchini, Novara, Giacomo, Parisi, Alice, Fracalanza, Simonetta, Martignoni, Guido, Artibani, Walter
Format: Article
Language:English
Subjects:
Aged
Biological and medical sciences
complications
Disease-Free Survival
Follow-Up Studies
Genital system. Mammary gland
HIFU
high‐intensity focused ultrasound
Humans
Male
Medical sciences
Nephrology. Urinary tract diseases
Postoperative Complications - etiology
Prospective Studies
Prostate-Specific Antigen - blood
prostatic neoplasm
Prostatic Neoplasms - diagnostic imaging
Prostatic Neoplasms - therapy
Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)
Risk Factors
Treatment Outcome
Tumors of the urinary system
Ultrasonography
Ultrasound, High-Intensity Focused, Transrectal
urinary continence
Urinary tract. Prostate gland
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:OBJECTIVE To assess the short‐term outcome in patients with high‐risk prostate cancer treated by transrectal high‐intensity focused ultrasound (HIFU). PATIENTS AND METHODS From April 2003 to November 2004, 30 patients with high‐risk prostate cancer were enrolled in this prospective study; all had transurethral resection of the prostate before transrectal HIFU treatment, using the Ablatherm device (EDAP, Lyon, France) during the same session, associated with hormonal therapy with luteinizing hormone‐releasing hormone analogues. After the procedure, all the patients were evaluated every 3 months by physical examination, prostate‐specific antigen (PSA) assay and a continence questionnaire. The follow‐up schedule also included a transperineal prostate biopsy 6 months after the treatment. All the patients had a minimum follow‐up of 12 months. RESULTS The HIFU treatment took a median (interquartile range, IQR) of 140 (100–160) min. No complications were reported during treatment. The mean (IQR) hospitalization was 2.2 (1–4) days, and the suprapubic drainage tube was removed after 12 (7–18) days. The complications after treatment were: urinary tract infections in five patients (16%), stenosis of the intraprostatic and membranous urethra in three (10%), and secondary infravesical obstruction in four (13%). At 12 months after the procedure, 28 patients (93%) were continent. Seven of the 30 men (23%) had a positive prostate biopsy. At the 1‐year follow‐up only three of the 30 patients with high‐risk prostate cancer had a PSA level of >0.3 ng/mL. CONCLUSIONS HIFU is a modern, minimally invasive therapy for prostate cancer, often used in selected patients with localized disease. The present results show that HIFU was also feasible in patients with high‐risk prostate cancer. The low complication rates and favourable functional outcome support the planning of further larger studies in such patients. The oncological efficacy of HIFU should be assessed in further studies with a longer follow‐up.
ISSN:1464-4096
1464-410X
DOI:10.1111/j.1464-410X.2006.06561.x